Remix Therapeutics Claimed Company
Remix Therapeutics is developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. Powered by our proprietary REMaster technology platform, we can now create medicines with the unique ability to alter the way genes are read from the genome, correcting dysregulation or eliminating the gene message altogether. These are innovative therapeutic solutions with the potential to address disease drivers at their origin. read more
Mike Seiler — Senior Director, Bioinformatics and Data Science at Remix Therapeutics
Executive Bio
Heading up computational biology, Michael brings a passion for RNA biology and processing to the Remix team. He joins with notable computational biology experience in the biotech space, most recently serving as head of computational biology at Arrakis Therapeutics and prior to that as a computational scientist leading splicing bioinformatics efforts at H3 Biomedicine. Michael completed his PhD in computational biology and molecular biophysics at Rutgers University and is excited to utilize his experience in further building a platform to harness powerful RNA processing to impact patients’ lives.
Executive Team Culture Ratings from Remix Therapeutics Employees
TOP
5%
Remix Therapeutics' Executive Team scores in the Top 5%
of similar sized companies on Comparably
of similar sized companies on Comparably
Remix Therapeutics' Executive Team at a Glance
Based on 66 ratings, Remix Therapeutics' employees are very satisfied with their Executive Team and give them an “A+” or 93/100. On average, Women provided higher ratings for their Executive Team compared to Men. Also, the Biomolecular Sciences and Lead Discovery department thinks more highly of the Executive Team relative to the Discovery Biology department.
Remix Therapeutics' Executive Team ranks in the Top 5% of other companies in Boston and Top 5% of other companies on Comparably that also have 51-200 Employees.
×